semaglutide oral approval Novo Nordisk wins EU for Wegovy weight-loss pill A new class of oral

A new federal program called the Medicare GLP-1 Bridge now lets eligible Medicare beneficiaries get certain weight-loss medications for about $50 a month

A medication that also affects glucagon may potentially influence energy expenditure and fat metabolism

The two policy moves happen on parallel calendars and serve different parts of the compounded-drug market

Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 1-2 oral antidiabetics: systematic review and network meta-analysis

The company is now planning more than 10 Phase 3 trials for berobenatide in 2026, signaling an attempt to build a broad obesity and comorbidity franchise that could reshape Pfizer's mix of future growth drivers